CanSino Biologics Inc (HKG: 06185), known in English as CANSINOBIO, has announced that its board of directors has resolved to grant a total of 287,400 restricted shares to 19 eligible incentive recipients.
The grants are scheduled to be made on September 16, 2026, designated as the reserved grant date, with an exercise price of RMB 41.20 per A-share. This allotment falls under the reserved grant portion of the company's 2025 A-share incentive plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.